Figure 3: UVRAG deficiency increases ROS production and apoptosis in DOX-induced cardiotoxicity.

(a) ROS levels in LVs detected using DCFH-DA 5 days after acute DOX or vehicle treatment. n = 3 mice for each group. (b) ROS levels in LVs detected using DCFH-DA at 4 weeks of DOX or vehicle treatment in chronic DOX cardiotoxicity. n = 3 mice for each group. (c) Quantification of apoptotic cells 5 days after acute DOX or vehicle treatment. n = 3 mice for each group. (d) Quantification of apoptotic cells at 4 weeks of DOX or vehicle treatment. (e) Western blot analysis of XIAP in LVs from WT and UVRAG-deficient mice 3 days after acute DOX or vehicle treatment. (f) Quantification of XIAP as illustrated in panel (e). (g) Western blot analysis of XIAP in LVs from WT and UVRAG-deficient mice at 4 weeks of chronic DOX treatment or vehicle treatment. (h) Quantification of XIAP as illustrated in panel (g). n = 3 mice for each group. *P < 0.05 vs. WT + vehicle, ^#P < 0.05 vs. WT + DOX.